EP3472623A4 - Exosomgesteuerte behandlung von krebs - Google Patents

Exosomgesteuerte behandlung von krebs Download PDF

Info

Publication number
EP3472623A4
EP3472623A4 EP17816131.1A EP17816131A EP3472623A4 EP 3472623 A4 EP3472623 A4 EP 3472623A4 EP 17816131 A EP17816131 A EP 17816131A EP 3472623 A4 EP3472623 A4 EP 3472623A4
Authority
EP
European Patent Office
Prior art keywords
exosome
cancer
guided treatment
guided
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17816131.1A
Other languages
English (en)
French (fr)
Other versions
EP3472623A1 (de
Inventor
Patrick Soon-Shiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nant Holdings IP LLC
Original Assignee
Nant Holdings IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings IP LLC filed Critical Nant Holdings IP LLC
Publication of EP3472623A1 publication Critical patent/EP3472623A1/de
Publication of EP3472623A4 publication Critical patent/EP3472623A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
EP17816131.1A 2016-06-21 2017-06-21 Exosomgesteuerte behandlung von krebs Withdrawn EP3472623A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352753P 2016-06-21 2016-06-21
PCT/US2017/038515 WO2017223186A1 (en) 2016-06-21 2017-06-21 Exosome-guided treatment of cancer

Publications (2)

Publication Number Publication Date
EP3472623A1 EP3472623A1 (de) 2019-04-24
EP3472623A4 true EP3472623A4 (de) 2020-01-15

Family

ID=60784697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17816131.1A Withdrawn EP3472623A4 (de) 2016-06-21 2017-06-21 Exosomgesteuerte behandlung von krebs

Country Status (11)

Country Link
US (1) US20190234955A1 (de)
EP (1) EP3472623A4 (de)
JP (1) JP2019527343A (de)
KR (1) KR20190032374A (de)
CN (1) CN109716135A (de)
AU (1) AU2017280204A1 (de)
CA (1) CA3027478A1 (de)
IL (1) IL263835A (de)
MX (1) MX2018015797A (de)
SG (1) SG11201811070SA (de)
WO (1) WO2017223186A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201902357A (zh) * 2017-05-02 2019-01-16 美商陶氏農業科學公司 用作種子處理之無環吡啶醯胺
US20200072843A1 (en) * 2018-08-30 2020-03-05 Mackay Memorial Hospital Methods of diagnosing diseases by extracellular vesicles and uses thereof
WO2021142088A1 (en) * 2020-01-07 2021-07-15 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
WO2021173994A1 (en) * 2020-02-27 2021-09-02 The Trustees Of The University Of Pennsylvania Methods of using a multi-analyte approach for diagnosis and staging a disease
CN115449555B (zh) * 2022-10-26 2023-10-13 山东大学 Adgra2作为乳腺癌化疗疗效和预后评价生物标志物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108294735B (zh) * 2012-03-13 2021-09-07 西门子公司 用于冠状动脉狭窄的非侵入性功能评估的方法和***
US11180812B2 (en) * 2012-08-17 2021-11-23 Cornell University Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease
CN105074468A (zh) * 2013-04-08 2015-11-18 盐野义制药株式会社 大肠癌的检测方法
WO2014166303A2 (en) * 2013-04-12 2014-10-16 The Chinese University Of Hong Kong Use of multiomic signature to predict diabetes
US9921223B2 (en) * 2013-12-04 2018-03-20 Board Of Regents, The University Of Texas System Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis
EP3161482B1 (de) * 2014-06-27 2020-08-26 XY Evergreen Technology Company Verfahren zur anreicherung von exosomen aus dem zns
CN104450901B (zh) * 2014-11-27 2016-09-21 广州赛哲生物科技股份有限公司 快速诊断川崎病的核酸标记物及其试剂盒

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DOUGLAS BRUBAKER ET AL: "DRUG INTERVENTION RESPONSE PREDICTIONS WITH PARADIGM (DIRPP) IDENTIFIES DRUG RESISTANT CANCER CELL LINES AND PATHWAY MECHANISMS OF RESISTANCE", BIOCOMPUTING 2014, 1 November 2013 (2013-11-01), pages 125 - 135, XP055562160, ISBN: 978-981-4583-22-0, DOI: 10.1142/9789814583220_0013 *
HOORN ET AL: "Prospects for urinary proteomics: exosomes as a source of uri nary biomarkers", NEPHROLOGY, BLACKWELL SCIENCE, CARLTON, AU, vol. 10, no. 3, 1 June 2005 (2005-06-01), pages 283 - 290, XP008139623, ISSN: 1320-5358, [retrieved on 20050401], DOI: 10.1111/J.1440-1797.2005.00387.X *
HUILIN SHAO ET AL: "Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy", NATURE MEDICINE, vol. 18, no. 12, 11 November 2012 (2012-11-11), New York, pages 1835 - 1840, XP055646100, ISSN: 1078-8956, DOI: 10.1038/nm.2994 *
HYUNGSOON IM ET AL: "Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor", NATURE BIOTECHNOLOGY, vol. 32, no. 5, 20 April 2014 (2014-04-20), pages 490 - 495, XP055207677, ISSN: 1087-0156, DOI: 10.1038/nbt.2886 *
PISITKUN TRAIRAK ET AL: "Identification and proteomic profiling of exosomes in human urine", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 101, no. 36, 7 September 2004 (2004-09-07), pages 13368 - 13373, XP002573117, ISSN: 0027-8424, DOI: 10.1073/PNAS.0403453101 *
See also references of WO2017223186A1 *

Also Published As

Publication number Publication date
IL263835A (en) 2019-02-03
JP2019527343A (ja) 2019-09-26
MX2018015797A (es) 2019-05-16
EP3472623A1 (de) 2019-04-24
AU2017280204A1 (en) 2019-01-24
KR20190032374A (ko) 2019-03-27
CA3027478A1 (en) 2017-12-28
US20190234955A1 (en) 2019-08-01
CN109716135A (zh) 2019-05-03
WO2017223186A1 (en) 2017-12-28
SG11201811070SA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
EP3548071A4 (de) Verfahren zur behandlung von krebs mit tigit-bindenden wirkstoffen
EP3423488A4 (de) Verfahren zur behandlung von krebs
EP3630089A4 (de) Verfahren für eine krebstherapie
EP3402517A4 (de) Immunologische behandlung von krebs
EP3393475A4 (de) Verfahren zur behandlung von krebs
EP3294065A4 (de) Verfahren zur behandlung von krebs
EP3432888A4 (de) Krebsbehandlung mit tg02
EP3307240A4 (de) Kombinationstherapie zur krebsbehandlung
EP3359192A4 (de) Kombinationstherapie zur krebsbehandlung
EP3389645A4 (de) Kombinationen zur behandlung von krebs
PL3458052T3 (pl) Leczenie skojarzone nowotworu
EP3548028A4 (de) Krebsbehandlung
EP3474854A4 (de) Krebsbehandlungskombinationen
EP3606531A4 (de) Verfahren zur behandlung von krebs
EP3442946A4 (de) Verfahren zur behandlung von krebs
EP3226901A4 (de) Kombinationstherapie zur behandlung von krebs
EP3185884A4 (de) Kombinationstherapie zur krebsbehandlung
EP3541417A4 (de) Kombinationsimmuntherapien zur behandlung von krebs
EP3490561A4 (de) Kombinationen zur behandlung von krebs
EP3503887A4 (de) Kombinationen zur behandlung von krebs
EP3325006A4 (de) Verfahren zur behandlung von cd166-exprimierendem krebs
EP3472623A4 (de) Exosomgesteuerte behandlung von krebs
EP3550976A4 (de) Verfahren zur synergistischen behandlung von krebs
EP3487999A4 (de) Verfahren zur behandlung von krebs
EP3484477A4 (de) Krebsbehandlung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191212

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20191206BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200520

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201001